



PRESS RELEASE

Uppsala March 9, 2011

Maria Carell resigns as President and CEO of Q-Med

Carina Bolin appointed as interim Chief Executive Officer

Today, March 9, 2011, Maria Carell is resigning from the position of President and Chief Executive Officer of Q-Med AB (publ), with immediate effect. The Board of Directors has appointed Carina Bolin, the company's General Counsel since 2002, as interim CEO.

“We were fortunate to recruit Maria to serve as President and CEO and in this capacity she has created real value for shareholders”, comments Anders Milton, Chairman of the Bid Committee¹ and Director of the Board. “We have been able to observe that Maria's leadership, her values and competence have delivered results. Through an increased sales and market focus, Q-Med's position as the leading company within esthetic beauty treatments has been strengthened.”

“It feels natural for me to leave now when Galderma is taking over,” says Maria Carell. “The role of CEO of a company listed on the stock exchange, for which I was recruited, no longer exists. Q-Med will now be integrated and become the esthetic division of Galderma. Q-Med is a fantastic company with great overall competence and I am proud of what Q-Med's organization has achieved. The merged company has a bright future, of that I am sure,” concludes Maria Carell.

“Maria's leadership and careful stewardship of Q-Med during this transition phase has been very much appreciated,” says Humberto C Antunes, President and CEO of Galderma. “We are impressed by Q-Med's accomplishments and are convinced our combined organization will be better able to serve our customers and expand this fast growing market.”

Carina Bolin, who will serve in the capacity of interim CEO, joined Q-Med in January 2000 as legal counsel. She has served in the capacity of General Counsel since 2002. Q-Med has applied for delisting of the Company's shares and has announced an Extraordinary General Meeting on March 28, as previously published on March 3, 2011 in a press release.

Queries should be addressed to:

Karin Falck, Head of Corporate Communications
Tel: +46 (0) 70-974 90 15

The information in this press release is such as that which Q-Med is required to disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for disclosure at 7.30 a.m. on March 9, 2011.

Q-Med AB is a medical device company that develops, manufactures, markets, and sells high quality medical implants for esthetic and medical use. The majority of the products are based on the company's patented technology, **NASHA™**, for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: **Restylane®** for filling lines and folds, contouring and creating volume in the face, **Macrolane™** for body contouring, **Durolane™** for the treatment of osteoarthritis of the hip and knee joints, **Deflux®** for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and **Solesta®** for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med has about 650 coworkers, with almost 400 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the NASDAQ OMX Nordic.

Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate identity number 556258-6882.
Tel: +46 18 474 90 00. Fax: +46 18 474 90 01. E-mail: info@q-med.com. Web: www.q-med.com

¹ The Bid Committee, which has been established by the Board, consists of the directors of the board Anders Milton, Bertil Hult and Ulf Mattson.